GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy
Genmab shares fell 3.3% to $31.45 after the company said it will stop developing late-stage cancer drug acasunlimab, citing a competitive landscape. The company will shift investment to other late-stage oncology programs and kept its 2025 guidance unchanged.